Developing new medicines often takes seven to ten years – a major challenge, especially in areas without existing therapies. Boehringer Ingelheim, together with Eraneos, took a bold step from a traditional project approach to an agile, product-centric way of working. With One Medicine Analytics, they created a digital ecosystem that makes complex medical data more accessible, breaks down silos, and accelerates decision-making in clinical development. This article highlights how such a transformation can succeed, the challenges faced along the way, and the key success factors that made it possible.
How can pharmaceutical companies break down rigid structures and bring digital innovation to life faster? Boehringer Ingelheim has launched its journey towards agile product development with One Medicine Analytics – supported by Eraneos. The result: more efficient processes, shorter development cycles, and a strong foundation for data-driven decision-making.
Download the article below to read the full story (PDF).
